Երկիր: Ինդոնեզիա
Լեզու: ինդոնեզերեն
Աղբյուրը: Badan Pengawas Obat dan Makanan RI - Indonesian Food and Drug Supervisory Agency
ACETYLSALICYLIC ACID; CLOPIDOGREL
AVENTIS PHARMA - Indonesia
ACETYLSALICYLIC ACID; CLOPIDOGREL
75/100 MG
TABLET SALUT SELAPUT
DUS, 3 BLISTER @ 10 TABLET SALUT ENTERIK
SANOFI-WINTHROP, FRANCE
2019-04-04
RANCANGAN LEAFLET COPLAVIX CLOPIDOGREL / ACETYLSALICYLIC ACID(ASA) COMPOSITION Each film-coated tablet contains 75 mg of clopidogrel (as hydrogen sulphate) and 100 mg of acetylsalicylic acid (ASA). PHARMACEUTICAL FORM Enteric Coated Tablet (tablet). Light pink, oval, slightly biconvex, engraved with «C75» on one side and «A100» on the other side. CLINICAL PARTICULARS THERAPEUTIC INDICATIONS CoPlavix is indicated for the secondary prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA). CoPlavix is a fixed-dose combination medicinal product for continuation of therapy in: - Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention - ST segment elevation acute myocardial infarction in medically treated patients eligible for thrombolytic therapy For futher information please refer to “_Pharmacodynamic properties_”. POSOLOGY AND METHOD OF ADMINISTRATION Posology Adults and elderly CoPlavix should be given as a single daily 75 mg/100 mg dose. CoPlavix is used following initiation of therapy with clopidogrel and ASA given separately. - In patients with non-ST segment elevation acute coronary syndrome (unstable angina or non-Q- wave myocardial infarction): The optimal duration of treatment has not been formally established. Clinical trial data support use up to 12 months, and the maximum benefit was seen at 3 months (see section 5.1). If the use of CoPlavix is discontinued, patients may benefit with continuation of one antiplatelet medicinal product. - In patients with ST segment elevation acute myocardial infarction: Therapy should be started as early as possible after symptoms start and continued for at least four weeks. The benefit of the combination of clopidogrel with ASA beyond four weeks has not been studied in this setting (see section 5.1). If the use of CoPlavix is discontinued, patients may benefit w Կարդացեք ամբողջական փաստաթուղթը